Vizgen

Harvard University professor and Howard Hughes Medical Institute investigator Xiaowei Zhuang invented MERFISH (Multiplexed Error-Robust Fluorescence In Situ Hybridization) and co-founded Vizgen to commercialize the technology. Zhuang's lab demonstrated MERFISH in a 2015 Science paper that showed imaging thousands of RNA species in single cells with error-robust barcoding. She remains a Scientific Co-founder of the firm.

MERSCOPE profiles gene expression directly within intact tissue, preserving the physical location of each transcript. Single-cell sequencing dissociates tissue and loses spatial context. MERSCOPE achieves sub-micron resolution and can image hundreds to thousands of genes across whole tissue sections, giving researchers cell-type maps with neighborhood-level architecture that is unavailable from dissociated methods.

Vizgen sells or leases MERSCOPE instruments to academic and pharmaceutical research labs, with recurring revenue from consumables — fluorescent probes, imaging reagents, and flow cells. The company also operates service labs where customers send tissue samples for outsourced spatial profiling. This instrument-plus-consumable model mirrors Illumina's sequencing hardware model.

Blue Water Life Sciences led Vizgen's $85 million Series C round in March 2022, with participation from ARCH Venture Partners and Northpond Ventures (per the firm, March 2022). Earlier investors include Tao Capital Partners and Softbank Vision Fund 2, which led a 2021 Series C extension. The investor base is a mix of life-sciences specialists and deep-tech crossover vehicles.

Vizgen focuses on preclinical and translational research rather than diagnostics. Academic and pharma customers use MERSCOPE for oncology — mapping tumor microenvironments — and for neuroscience, where spatial organization of cell types in brain tissue is critical. Immunology and developmental biology labs also use the platform to study tissue organization at the transcriptomic level.

10x Genomics offers the Visium platform, which captures spatial gene expression but does not achieve single-cell resolution, and the newer Xenium platform with multiplexed single-molecule FISH. Nanostring's CosMx SMI instrument also uses FISH-based chemistry for single-cell spatial profiling. Vizgen's differentiator is the underlying MERFISH error-robust barcoding scheme, which allows highly multiplexed gene panels with inherent error correction — a direct consequence of the academic research behind it.

Vizgen is a life-sciences research-tools company. MERSCOPE is sold for research use only, not for clinical diagnostics. The firm operates in the preclinical and translational-research segment of the spatial biology market, selling to pharma R&D groups and academic core facilities. There is no public indication that Vizgen is pursuing FDA-regulated diagnostic applications.